Lilly's $410 Million Jardiance Milestone Was The Last One — No More Payments Remain

Lilly booked $910 million in Jardiance milestones over nine months, and its 10-Q says none are left to earn.

Share
Lilly's $410 Million Jardiance Milestone Was The Last One — No More Payments Remain

Eli Lilly, the drugmaker behind Mounjaro and Zepbound, booked $410 million of Jardiance sales milestones in the third quarter, and its 10-Q says no further milestones remain to be earned. The payments, tied to its collaboration with Boehringer Ingelheim, totaled $910 million over the first nine months of 2026.

A payment stream that peaked and ended

The milestones padded a quarter in which revenue rose 39% to $24.4 billion. Lilly's earnings release put total third-quarter benefits at about $900 million, mostly the Jardiance payment plus favorable adjustments to rebate and discount estimates.

The prior quarterly filing said Lilly had the right to receive up to $410 million in 2026 milestones, and $500 million had been recognized in six months. The full $410 million then arrived in the third quarter. A year earlier, Lilly recognized $200 million in Jardiance milestones in the quarter.

Rebate and discount estimate adjustments equaled 2% of U.S. revenue in the quarter, against less than 1% a year earlier. Lilly still shares in Jardiance net sales through the end of 2028 in the most significant markets, which it books as collaboration revenue.

Volume up, price down

Lilly's growth is volume-led. A 53% rise in volume in the quarter was partly offset by a 15% drop in realized prices. Mounjaro, Zepbound and Foundayo made up 66% of nine-month revenue.

Diluted earnings per share were $7.22, up 16%, after $4.57 per share of acquired research charges tied to deals. Net income was $6.5 billion for the quarter. Lilly raised its 2026 revenue guidance to $91.0 billion to $92.0 billion, but trimmed its adjusted earnings guidance to $35.00 to $36.00 because of the deal charges.

Lilly discovers, develops, makes and sells medicines for diabetes and obesity, cancer, immune conditions and neurological disease.

Debt, buybacks and a new tax exam

Total debt stood at $49.5 billion at September 30, up $7.0 billion from $42.5 billion at year-end. Lilly had $6.6 billion left on its $15.0 billion buyback program, versus $7.0 billion at June 30.

On Medicare, the 10-Q says the GLP-1 Bridge program gives beneficiaries discounted obesity drugs from July 1, 2026 through December 31, 2027, and that continued uptake from that access "is unknown." The IRS also began examining tax years 2022-2024 in October.

Lilly declared a fourth-quarter dividend of $1.73 per share, payable December 10 to holders of record on November 13. In October it bought Merida for up to $2.9 billion including milestone payments. The stock was up 6.25% in Thursday trading, with a market value of $1.15 trillion.

With the Jardiance payments finished, the fourth quarter will show how much of Lilly's revenue growth stands without them.

Sources

More on Eli Lilly and

All Eli Lilly and (LLY) coverage →